TRV734 is a drug developed by Trevena, Inc. which acts as a biased agonist at the ü-opioid receptor, selective for activation of the G protein signaling pathway over ò-arrestin 2 recruitment. It is closely related to oliceridine (TRV130) and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally. The drug reached phase 2 clinical trials for treatment of pain but was discontinued for this indication. It is also under development for treatment of opioid-related disorders, in association with the National Institute on Drug Abuse (NIDA) and having reached phase 1 trials for this use, but no recent development has been reported.